For example, MSNP-PEI-PEG nanoparticles with si-HER2 (against the mRNA of HER2) have been demonstrated to inhibit the growth of breast cancer HCC1954 lineages, which are otherwise unresponsive to anti-HER2 antibodies (trastuzumab) [257]. Here, ERBB2 is linked to breast carcinoma.